B. Riley lowered the firm’s price target on Radiopharm (RADX) to $13 from $15 and keeps a Buy rating on the shares. Radiopharm, which recently reported clinical progress across four lead programs, has an attractive risk/reward profile with key catalysts expected over the next 6-12 months, the analyst tells investors in a research note. With two additional assets entering clinics, some of Radiopharm’s clinical-stage assets may be pursued by pharma when the market’s interest in RLT returns, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm receives approval to initiate Phase 1 trial of RAD 402
- Radiopharm announces 50% enrollment in Phase 2b trial of RAD101
- Radiopharm starts enrollment of third cohort in Phase 1 trial of 177Lu-RAD204
- Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Resolutions
- Radiopharm Theranostics Limited: Promising Financial and Clinical Outlook Justifies Buy Rating